MEDICAMENTAL TREATMENT OF FEMALE AND MALE FEMALE DYSFUNCTIONS WITH THE VARIOUS ANTIDEPRESSIVE GROUPS； ASSOCIATED TO ANDROGEN DRUGS (TESTOSTERONE), ESTROGENICS (ESTRADIOL), INBITORIAL NEUROTRANSMISSOR (GABA) AND SOME VASODILATORS, WHICH HAVE PENIAN EFFECTIVE ACTION (VARDENAFIL, SILDENAFIL AND TADALAFIL). MAY BE IN ASSOCIATION OR ISOLATED AND BE INDUSTRIALIZED AND MARKETED, IN VARIOUS FORMS OF PRESENTATION AND POSOLOGY. THERAPEUTIC INDICATION FOR PATIENTS WITH DEPRESSION FRAMEWORK AND / OR BIPOLAR DISORDER, WHO NEED TO USE ANTIDEPRESSIVE DRUGS, OBJECTING THE REDUCTION OR ABOLITION OF THE SEXUAL
This patent refers to the chemical -pharmaceutical sector. This patent is characterised by associating various groups of antidepressant drugs with various other groups of substances, whether associated or isolated, such as: groups of androgens (testosterone),Neurotransmitter inhibitory -gaba, estrogen (estradiol),Some vasodilators with penile erective action, such as vardenafil, sildenafil and tadalafil, totalling in their associations 205 new pharmacological products, for treatments of the different female and male sexual dysfunctions, which affect the following stages: stage of the Sejo, stimulation phase, orgasm phase, producing increased sexual function of patients who make use of antidepressant drugs, which, for the most part, produce reduced sexual performance,In both men and women. The benefit is to improve these difficulties in men with premature ejaculation who have to undergo treatments with antidepressant drugs, of all kinds, another group is the ones with erective difficulties, or who already have or are produced by the anti -depressant medicine Resentful. The vast majority of antidepressants, regardless of the group to which they belong, produce a reduction in sexual desire in both sexes, and this patent proposes some medications that can improve these dysfunctions, as well as, in women in weather,Many of them already possess or begin to produce sexual dysfunctions with the use of antidepressants. Can be industrialised and marketed in the most different forms and posologies.esta patente refere-se ao setor químico-farmacêutico. esta patente caracteriza-se por associar diversos grupos de drogas antidepressivas à vários outros grupos de substâncias, quer estejam associadas ou isoladas, tais como: grupos de andrógenos (testosterona), neurotransmissor inibitório - gaba, estrogênio (estradiol), alguns vasodilatadores com ação eretiva peniana, tais como, vardenafil, sildenafil e tadalafil, totalizando em suas associações 205 novos produtos farmacológicos difer
